A detailed history of N Verses Capital, LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, N Verses Capital, LLC holds 10,300 shares of EXEL stock, worth $272,332. This represents 0.14% of its overall portfolio holdings.

Number of Shares
10,300
Holding current value
$272,332
% of portfolio
0.14%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 31, 2024

BUY
$20.34 - $23.73 $209,502 - $244,419
10,300 New
10,300 $231 Million

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $8.51B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track N Verses Capital, LLC Portfolio

Follow N Verses Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of N Verses Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on N Verses Capital, LLC with notifications on news.